Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 18/20 | 0.63 |
| ▸ | FBP1 | P09467 | 2/20 | 0.60 |
| ▸ | ERBB2 | P04626 | 2/20 | 0.60 |
| ▸ | AURKA | O14965 | 1/20 | 0.60 |
| ▸ | INSR | P06213 | 1/20 | 0.60 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.60 |
| ▸ | FLT4 | P35916 | 1/20 | 0.60 |
| ▸ | KDR | P35968 | 1/20 | 0.60 |
| ▸ | CLK1 | P49759 | 1/20 | 0.60 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.60 |
| ▸ | TEK | Q02763 | 1/20 | 0.60 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.60 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29615011 | 1.00 | EGFR (0.63) | EGFRFBP1ERBB2AURKAINSR | |
| SCHEMBL30237488 | 1.00 | EGFR (0.63) | EGFRFBP1ERBB2AURKAINSR | |
| Hydrochloric Acid SCHEMBL4780920 | 0.99 | EGFR (0.62) | EGFRFBP1ERBB2AURKAINSR | |
| SCHEMBL1366535 | 0.93 | EGFR (0.68) | EGFRFBP1ERBB2AURKAINSR | |
| SCHEMBL30294136 | 0.93 | EGFR (0.68) | EGFRFBP1ERBB2AURKAINSR | |
| Hydrochloric Acid SCHEMBL8314953 | 0.92 | EGFR (0.67) | EGFRFBP1ERBB2AURKAINSR | |
| SCHEMBL28413582 | 0.91 | EGFR (0.59) | EGFRFBP1ERBB2AURKAINSR | |
| SCHEMBL3246075 | 0.90 | EGFR (0.61) | EGFRFBP1ERBB2AURKAINSR | |
| SCHEMBL18862887 | 0.90 | EGFR (0.60) | EGFRFBP1ERBB2AURKAINSR | |
| SCHEMBL5097627 | 0.90 | EGFR (0.61) | EGFRFBP1ERBB2AURKAINSR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 243 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113861120-A | Preparation method of dacomitinib | 湖南南新制药股份有限公司 | 2021-12-31 | — | — | CN | claimed |
| CN-111548314-B | Production method of N- (3-chloro-4-fluorophenyl) -7-fluoro-6-nitro-4-quinazolinamine | 上海万巷制药有限公司 | 2021-09-03 | — | — | CN | claimed |
| CN-109206377-B | Novel method for preparing N- (3-chloro-4-fluorophenyl) -7-fluoro-6-nitro-4-quinazolinamine | 江苏食品药品职业技术学院 | 2021-08-27 | — | — | CN | claimed |
| CN-111548314-A | Production method of N- (3-chloro-4-fluorophenyl) -7-fluoro-6-nitro-4-quinazolinamine | 上海万巷制药有限公司 | 2020-08-18 | — | — | CN | claimed |
| US-10550107-B2 | Process for the preparation of N-[4-[(3-chloro-4-fluoro phenyl) amino]-7-[[(3s-tetrahydro-3-furanyl]oxy]-6-quinazolinyl]-4-(dimethyl amino)-(2E)-2-butenamide (2Z)-2-butenedioate (1:2) and its polymorphs thereof | MSN LABORATORIES PRIVATE LIMITED (IN) | 2020-02-04 | — | — | US | claimed |
| US-20180297989-A1 | PROCESS FOR THE PREPARATION OF N-[4-[(3-CHLORO-4-FLUORO PHENYL) AMINO]-7-[[(3s-TETRAHYDRO-3-FURANYL]OXY]-6-QUINAZOLINYL]-4-(DIMETHYL AMINO)-(2E)-2-BUTENAMIDE (2Z)-2-BUTENEDIOATE (1 :2) AND ITS POLYMORPHS THEREOF | MSN LABORATORIES PRIVATE LIMITED (IN) | 2018-10-18 | — | — | US | claimed |
| US-20240382599-A1 | EGFR PROTEOLYSIS TARGETING CHIMERIC MOLECULES AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. | 2024-11-21 | — | — | US | disclosed |
| CN-118063399-A | Method for synthesizing N- (3-chloro-4-fluorophenyl) -6-hydroxy-7-methoxy-4-quinazolinamine | 杭州微流汇科技有限公司 | 2024-05-24 | — | — | CN | disclosed |
| CN-117304170-A | Bifunctional molecule capable of degrading EGFR mutant and preparation method and application thereof | 中国药科大学 | 2023-12-29 | — | — | CN | disclosed |
| CN-115703817-A | Bifunctional molecule for targeted degradation of EGFR mutant and preparation method and application thereof | 中国药科大学 | 2023-02-17 | — | — | CN | disclosed |
| WO-2022184119-A1 | TYROSINE KINASE INHIBITOR AND PHARMACEUTICAL USE THEREOF | 江苏康可得生物技术股份有限公司 | 2022-09-09 | — | — | WO | disclosed |
| CN-114394942-A | Tyrosine kinase inhibitor and pharmaceutical application thereof | 江苏康可得生物技术股份有限公司 | 2022-04-26 | — | — | CN | disclosed |
| CN-113861120-A | Preparation method of dacomitinib | 湖南南新制药股份有限公司 | 2021-12-31 | — | — | CN | disclosed |
| EP-1131304-A1 | N- 4-(3-CHLORO-4-FLUORO-PHENYLAMINO)-7-(3-MORPHOLIN-4-YL-PROPOXY)-QUINAZOLIN-6-YL]-ACRYLAMIDE, AN IRREVERSIBLE INHIBITOR OF TYROSINE KINASES | WARNER-LAMBERT COMPANY (US) | 2001-09-12 | — | — | EP | disclosed |
| WO-2001036003-A2 | SELECTIVE CELLULAR TARGETING: MULTIFUNCTIONAL DELIVERY VEHICLES | DRUG INNOVATION & DESIGN, INC. (US) | 2001-05-25 | — | — | WO | disclosed |
| EP-0635498-B1 | Quinazoline derivatives and their use as anti-cancer agents | SYNGENTA LTD (GB) | 2001-04-18 | — | — | EP | disclosed |
| WO-2000031048-A1 | N-[4-(3-CHLORO-4-FLUORO-PHENYLAMINO)-7-(3-MORPHOLIN-4-YL-PROPOXY)-QUINAZOLIN-6-YL]-ACRYLAMIDE, AN IRREVERSIBLE INHIBITOR OF TYROSINE KINASES | WARNER-LAMBERT COMPANY (US) | 2000-06-02 | — | — | WO | disclosed |
| US-5475001-A | Quinazoline derivatives | ZENECA LIMITED (GB) | 1995-12-12 | — | — | US | disclosed |
| WO-1995003283-A1 | QUINAZOLINE DERIVATIVES AND THEIR USE AS ANTI-CANCER AGENTS | ZENECA LIMITED (GB) | 1995-02-02 | — | — | WO | disclosed |
| EP-0635498-A1 | Quinazoline derivatives and their use as anti-cancer agents | ZENECA LIMITED (GB) | 1995-01-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10550107-B2 | Process for the preparation of N-[4-[(3-chloro-4-fluoro phenyl) amino]-7-[[(3s-tetrahydro-3-furanyl]oxy]-6-quinazolinyl]-4-(dimethyl amino)-(2E)-2-butenamide (2Z)-2-butenedioate (1:2) and its polymorphs thereof | CYP4B1, CYP1B1, CYP2S1 | EGFR 4240/4885FBP1 917/4885ERBB2 2343/4885 |
| US-20180297989-A1 | PROCESS FOR THE PREPARATION OF N-[4-[(3-CHLORO-4-FLUORO PHENYL) AMINO]-7-[[(3s-TETRAHYDRO-3-FURANYL]OXY]-6-QUINAZOLINYL]-4-(DIMETHYL AMINO)-(2E)-2-BUTENAMIDE (2Z)-2-BUTENEDIOATE (1 :2) AND ITS POLYMORPHS THEREOF | CYP4B1, CYP1B1, CYP2S1 | EGFR 4240/4885FBP1 917/4885ERBB2 2343/4885 |
| US-20240382599-A1 | EGFR PROTEOLYSIS TARGETING CHIMERIC MOLECULES AND ASSOCIATED METHODS OF USE | TBK1, EGFR, CBL | EGFR 2/4885FBP1 2591/4885ERBB2 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.